Oppenheimer Asset Management Inc. Increases Stock Position in Stevanato Group S.p.A. (NYSE:STVN)

Oppenheimer Asset Management Inc. lifted its holdings in shares of Stevanato Group S.p.A. (NYSE:STVN) by 59.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,941 shares of the company’s stock after acquiring an additional 4,441 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Stevanato Group were worth $219,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of STVN. Conestoga Capital Advisors LLC grew its position in shares of Stevanato Group by 48.7% during the first quarter. Conestoga Capital Advisors LLC now owns 6,778,893 shares of the company’s stock worth $217,602,000 after acquiring an additional 2,221,615 shares during the last quarter. Jackson Square Partners LLC lifted its holdings in shares of Stevanato Group by 763.9% during the first quarter. Jackson Square Partners LLC now owns 1,824,240 shares of the company’s stock worth $58,558,000 after purchasing an additional 1,613,075 shares during the period. Altitude Crest Partners Inc. acquired a new stake in shares of Stevanato Group during the first quarter worth $17,655,000. Thornburg Investment Management Inc. lifted its holdings in shares of Stevanato Group by 279.1% during the second quarter. Thornburg Investment Management Inc. now owns 746,218 shares of the company’s stock worth $13,690,000 after purchasing an additional 549,378 shares during the period. Finally, William Blair Investment Management LLC lifted its holdings in shares of Stevanato Group by 50.1% during the first quarter. William Blair Investment Management LLC now owns 1,432,868 shares of the company’s stock worth $45,995,000 after purchasing an additional 478,260 shares during the period.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on STVN. Citigroup decreased their price target on Stevanato Group from $30.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, August 7th. Morgan Stanley decreased their price target on Stevanato Group from $26.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of €29.25 ($32.50).

Stevanato Group Price Performance

Stevanato Group stock opened at €19.26 ($21.40) on Monday. Stevanato Group S.p.A. has a one year low of €16.56 ($18.40) and a one year high of €35.56 ($39.51). The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.13 and a current ratio of 1.74. The business has a fifty day moving average of €20.30 and a two-hundred day moving average of €22.75. The company has a market cap of $5.69 billion, a P/E ratio of 35.02, a price-to-earnings-growth ratio of 5.50 and a beta of 0.59.

Stevanato Group (NYSE:STVN) last released its earnings results on Tuesday, August 6th. The company reported €0.09 ($0.10) EPS for the quarter, missing analysts’ consensus estimates of €0.10 ($0.11) by (€0.01) (($0.01)). Stevanato Group had a net margin of 11.27% and a return on equity of 10.89%. The business had revenue of €259.60 million during the quarter, compared to analyst estimates of €254.92 million. During the same period last year, the business posted $0.15 EPS. Stevanato Group’s revenue was up 1.7% compared to the same quarter last year. As a group, analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.